Jump to main content
Jump to site search

Issue 11, 2018
Previous Article Next Article

Assessment of a bifendate derivative bearing a 6,7-dihydro-dibenzo[c,e]azepine scaffold as a potential anti-metastatic agent

Author affiliations

Abstract

Multidrug resistance (MDR) and metastasis are major causes of mortality in patients with cancer. We recently reported a bifendate derivative bearing a dibenzo[c,e]azepine scaffold (4i) as a P-gp and BCRP-medicated MDR reversal agent. As a continuation of the previous research, its ability to inhibit cancer metastasis was investigated in MDA-MB-231 cells in the present work. Wound-healing and chamber migration assays showed that 4i could significantly attenuate the migration of MDA-MB-231 cells. Additionally, 4i obviously suppressed the invasive activity of MDA-MB-231 cells, thus displaying potential anti-metastasis activity. Preliminary mechanism studies indicated that the anti-metastasis activity of 4i was associated with the inhibitory effect on the activity and expression of MMP-2 and MMP-9. These results, together with the previous findings, suggest that compound 4i could be a promising lead for the development of novel anti-cancer agents with anti-MDR and metastatic activities.

Graphical abstract: Assessment of a bifendate derivative bearing a 6,7-dihydro-dibenzo[c,e]azepine scaffold as a potential anti-metastatic agent

Back to tab navigation

Supplementary files

Article information


Submitted
11 Jun 2018
Accepted
17 Sep 2018
First published
17 Sep 2018

Med. Chem. Commun., 2018,9, 1826-1830
Article type
Research Article

Assessment of a bifendate derivative bearing a 6,7-dihydro-dibenzo[c,e]azepine scaffold as a potential anti-metastatic agent

J. Qiu, W. Chen, Y. Jiang, J. Chen, Y. Zhang and X. Gu, Med. Chem. Commun., 2018, 9, 1826
DOI: 10.1039/C8MD00294K

Search articles by author

Spotlight

Advertisements